152 related articles for article (PubMed ID: 20926021)
61. Effects of different omeprazole dosing on gastric pH in non-variceal upper gastrointestinal bleeding: A randomized prospective study.
Chwiesko A; Charkiewicz R; Niklinski J; Luczaj W; Skrzydlewska E; Milewski R; Baniukiewicz A; Wroblewski E; Rosolowski M; Dabrowski A
J Dig Dis; 2016 Sep; 17(9):588-599. PubMed ID: 27518195
[TBL] [Abstract][Full Text] [Related]
62. Endoscopic analysis of gastric ulcer after one week's treatment with omeprazole and rabeprazole in relation to CYP2C19 genotype.
Ando T; Ishikawa T; Kokura S; Naito Y; Yoshida N; Yoshikawa T
Dig Dis Sci; 2008 Apr; 53(4):933-7. PubMed ID: 17934830
[TBL] [Abstract][Full Text] [Related]
63. Esophageal mucosal injury with low-dose aspirin and its prevention by rabeprazole.
Sugimoto M; Nishino M; Kodaira C; Yamade M; Ikuma M; Tanaka T; Sugimura H; Hishida A; Furuta T
J Clin Pharmacol; 2010 Mar; 50(3):320-30. PubMed ID: 19940233
[TBL] [Abstract][Full Text] [Related]
64. CYP2C19 genotype and the PPIs--focus on rabeprazole.
Lim PW; Goh KL; Wong BC
J Gastroenterol Hepatol; 2005 Dec; 20 Suppl():S22-8. PubMed ID: 16359346
[TBL] [Abstract][Full Text] [Related]
65. Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status.
Uno T; Shimizu M; Yasui-Furukori N; Sugawara K; Tateishi T
Br J Clin Pharmacol; 2006 Mar; 61(3):309-14. PubMed ID: 16487224
[TBL] [Abstract][Full Text] [Related]
66. Comparison of the interaction potential of a new proton pump inhibitor, E3810, versus omeprazole with diazepam in extensive and poor metabolizers of S-mephenytoin 4'-hydroxylation.
Ishizaki T; Chiba K; Manabe K; Koyama E; Hayashi M; Yasuda S; Horai Y; Tomono Y; Yamato C; Toyoki T
Clin Pharmacol Ther; 1995 Aug; 58(2):155-64. PubMed ID: 7648765
[TBL] [Abstract][Full Text] [Related]
67. Effect of lansoprazole and rabeprazole on tacrolimus pharmacokinetics in healthy volunteers with CYP2C19 mutations.
Itagaki F; Homma M; Yuzawa K; Nishimura M; Naito S; Ueda N; Ohkohchi N; Kohda Y
J Pharm Pharmacol; 2004 Aug; 56(8):1055-9. PubMed ID: 15285851
[TBL] [Abstract][Full Text] [Related]
68. Clopidogrel and proton pump inhibitor (PPI) interaction: separate intake and a non-omeprazole PPI the solution?
Kenngott S; Olze R; Kollmer M; Bottheim H; Laner A; Holinski-Feder E; Gross M
Eur J Med Res; 2010 May; 15(5):220-4. PubMed ID: 20562062
[TBL] [Abstract][Full Text] [Related]
69. Early effects of Lansoprazole orally disintegrating tablets on intragastric pH in CYP2C19 extensive metabolizers.
Yamagishi H; Koike T; Ohara S; Horii T; Kikuchi R; Kobayashi S; Abe Y; Iijima K; Imatani A; Suzuki K; Hishinuma T; Goto J; Shimosegawa T
World J Gastroenterol; 2008 Apr; 14(13):2049-54. PubMed ID: 18395905
[TBL] [Abstract][Full Text] [Related]
70. Sufficient effect of 1-week omeprazole and amoxicillin dual treatment for Helicobacter pylori eradication in cytochrome P450 2C19 poor metabolizers.
Aoyama N; Tanigawara Y; Kita T; Sakai T; Shirakawa K; Shirasaka D; Kodama F; Okumura K; Kasuga M
J Gastroenterol; 1999; 34 Suppl 11():80-3. PubMed ID: 10616772
[TBL] [Abstract][Full Text] [Related]
71. Effects of omeprazole on intragastric pH and plasma gastrin are dependent on the CYP2C19 polymorphism.
Sagar M; Tybring G; Dahl ML; Bertilsson L; Seensalu R
Gastroenterology; 2000 Sep; 119(3):670-6. PubMed ID: 10982760
[TBL] [Abstract][Full Text] [Related]
72. Drug-drug interaction of rabeprazole and clopidogrel in healthy Chinese volunteers.
Wu J; Jia LT; Shao LM; Chen JM; Zhong DD; Xu S; Cai JT
Eur J Clin Pharmacol; 2013 Feb; 69(2):179-87. PubMed ID: 22706585
[TBL] [Abstract][Full Text] [Related]
73. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Furuta T; Shirai N; Sugimoto M; Nakamura A; Hishida A; Ishizaki T
Drug Metab Pharmacokinet; 2005 Jun; 20(3):153-67. PubMed ID: 15988117
[TBL] [Abstract][Full Text] [Related]
74. Efficacy of low-dose proton pump inhibitor (PPI) in the eradication of Helicobacter pylori following combination PPI/AC therapy in Japan.
Kawai T; Kawakami K; Mikinori K; Takei K; Itoi T; Moriyasu F; Takagi Y; Aoki T; Watanebe K; Matsumoto Y; Rimbara E; Noguchi N; Sasatsu M
Hepatogastroenterology; 2007 Mar; 54(74):649-54. PubMed ID: 17523342
[TBL] [Abstract][Full Text] [Related]
75. Acid inhibition effect of ilaprazole on Helicobacter pylori-negative healthy volunteers: an open randomized cross-over study.
DU YQ; Guo WY; Zou DW; Zhan XB; Li Z; Hu JH; Gong YF; He J; Lu JP; Li ZS
J Dig Dis; 2012 Feb; 13(2):113-9. PubMed ID: 22257480
[TBL] [Abstract][Full Text] [Related]
76. One-day front-loading with four doses of rabeprazole followed by a standard twice-daily regimen provides sufficient acid inhibition in extensive metabolizers of CYP2C19.
Kagami T; Sugimoto M; Ichikawa H; Sahara S; Uotani T; Yamade M; Hamaya Y; Iwaizumi M; Osawa S; Sugimoto K; Miyajima H; Furuta T
Eur J Clin Pharmacol; 2015 Dec; 71(12):1467-75. PubMed ID: 26427705
[TBL] [Abstract][Full Text] [Related]
77. Pharmacokinetics and Pharmacodynamics of Azeloprazole Sodium, a Novel Proton Pump Inhibitor, in Healthy Japanese Volunteers.
Toda R; Shiramoto M; Komai E; Yoshii K; Hirayama M; Kawabata Y
J Clin Pharmacol; 2018 Apr; 58(4):425-433. PubMed ID: 29193126
[TBL] [Abstract][Full Text] [Related]
78. Pharmacokinetic- pharmacodynamic analysis of the role of CYP2C19 genotypes in short-term rabeprazole-based triple therapy against Helicobacter pylori.
Yang JC; Yang YF; Uang YS; Lin CJ; Wang TH
Br J Clin Pharmacol; 2009 May; 67(5):503-10. PubMed ID: 19552744
[TBL] [Abstract][Full Text] [Related]
79. [The effect of proton pump inhibitor on intragastric acidity and it relation to S-mephenytoin hydroxylase genetic polymorphism].
Wang H; Nie YQ; Dai SJ; She QZ; Li YY
Zhonghua Nei Ke Za Zhi; 2003 Nov; 42(11):777-80. PubMed ID: 14636465
[TBL] [Abstract][Full Text] [Related]
80. Pharmacodynamic studies on PPIs: look carefully at the country of origin.
Savarino V; Savarino E; Dulbecco P
Dig Liver Dis; 2006 Nov; 38(11):808-10. PubMed ID: 16945598
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
